Cargando…
Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor‐negative and HER2‐positive breast cancer?
BACKGROUND: HER2+ and hormone receptor (HoR)‐negative breast cancer usually associated with poor outcome. However, it remained elusive for the prognosis of small (T1a‐T1c) HER2+/HoR‐ breast cancer. The present study retrospectively analyzed the Surveillance, Epidemiology, and End Results (SEER) data...
Autores principales: | Wang, Changjun, Zhou, Yidong, Zhu, Hanjiang, Huang, Wei, Chen, Ziyuan, Mao, Feng, Lin, Yan, Zhang, Xiaohui, Shen, Songjie, Zhong, Ying, Li, Yan, Sun, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246936/ https://www.ncbi.nlm.nih.gov/pubmed/30277006 http://dx.doi.org/10.1002/cam4.1785 |
Ejemplares similares
-
Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value
por: Wang, Changjun, et al.
Publicado: (2020) -
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
por: Wang, Changjun, et al.
Publicado: (2020) -
The impact of pre-existed and SERM-induced non-alcoholic fatty liver disease on breast cancer survival: a meta-analysis
por: Wang, Changjun, et al.
Publicado: (2020) -
Staging of ovarian cancer: time to subdivide more?
por: Denny, Lynette
Publicado: (2013) -
Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)